Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave

Lee, Matthew; Quinn, Ryann; Pradhan, Kith; Fedorov, Kateryna; Levitz, David; Fromowitz, Ariel; Thakkar, Astha; Shapiro, Lauren C.; Kabarriti, Rafi; Ruíz, Rafael; Andrews, Erin E.; Thota, Raja; Chu, Edward; Kalnicki, Shalom; Goldstein, Yitz; Loeb, David M.; Racine, Andrew D.; Halmos, Balázs; Mehta, Vikas; Verma, Amit

doi:10.1016/j.ccell.2022.02.012

Cited by 37 publications

(36 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case fatality rate of 4% observed in this study was comparable to the 4.9% reported in a recent retrospective study of 285 patients with both solid and hematological cancers in New York. [10] Our study compliments these findings with observations from within the United Kingdom with a focus on hematological malignancies. 26% of patients in this study were asymptomatic at presentation.…”

supporting

confidence: 85%

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

et al. 2022

View full text Add to dashboard Cite

supporting

confidence: 85%

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

et al. 2022

View full text Add to dashboard Cite

“…Over time, mortality in the general population versus mortality in members of the population who are infected has decreased during the different waves of the pandemic [ 21 ], which is likely due to multiple factors, including country-dependent public health measures, vaccination, and improved management of severe acute COVID-19 disease. However, patients with cancer, in general, have been shown to have reduced immune responses to vaccination and can present with severe COVID-19 [ 22 , 23 , 24 ]. It is important to note that following the first wave of the pandemic, the volume of cancer-directed therapies offered to patients returned to normal levels.…”

Section: Discussionmentioning

confidence: 99%

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Wysocki

Zhou

Rogado

et al. 2022

Cancers

View full text Add to dashboard Cite

Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.

show abstract

“…This concurred with the lower mortality rate observed in adult oncology patients infected during the Omicron wave in New York. 5 Uniquely, there had not been any documented infection in children undergoing oncologic therapy prior to the Omicron wave in Hong Kong, and the majority of our patients had not been vaccinated against SARS‐CoV‐2, implying that the observed disease course largely reflects that in children without prior immunity. In spite of the above, COVID‐19 commonly resulted in treatment interruption and may adversely impact the oncologic outcome; the persistent viral detection observed also promotes the acquisition of mutations in the viral genome.…”

mentioning

confidence: 82%

SARS‐CoV‐2 infection in children undergoing oncologic treatment in Hong Kong: A population‐based cohort during the Omicron wave

Liu

Lam²,

Chan³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave

Cited by 37 publications

References 6 publications

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

SARS‐CoV‐2 infection in children undergoing oncologic treatment in Hong Kong: A population‐based cohort during the Omicron wave

Contact Info

Product

Resources

About